STERIS (STE) has been drawing fresh attention after recent price moves left the stock down over the past month yet slightly higher over the past 3 months, prompting investors to reassess its health care sterilization business.
Across 2024, STERIS has given investors a mixed ride, with the share price down 12.64% year to date and the 1 year total shareholder return lower by 11.08%, while a 4.97% 90 day share price gain suggests recent momentum has started to cool again after a stronger early summer stretch.
Compare STERIS’s recent pullback with other healthcare equipment stocks by scanning a hand picked shortlist of list of solid balance sheet and fundamentals (24 results) that may offer similar resilience with different price setups.
STERIS shares have slipped again after a brief rebound, which puts a spotlight on an awkward question. Is this price reset tracking real business fundamentals or is it just sentiment swinging around a solid infection control franchise, and what does that imply for valuation today?
Most Popular Narrative: 16.7% Undervalued
With STERIS last closing at $218.44 against a widely followed fair value estimate of about $262, the narrative on this infection prevention specialist is leaning toward underpricing and focuses on how recurring chemistries, services, and capital spending might reshape its future earnings mix.
Continued expansion of STERIS's consumables and services segments with high recurring revenue and margin visibility positions the company to benefit from increasing healthcare expenditures and adoption of best practice infection control standards, supporting both revenue and margin expansion.
The 16.7% gap reflects a narrative built around steady top line expansion, rising profitability, and a future earnings multiple that assumes investors continue to value that profile at a premium. It can be useful to review which specific growth and margin targets have been incorporated into that model, and how a single assumption about profitability in a few years can influence the entire fair value estimate.
Result: Fair Value of $262.25 (UNDERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
Still, tariffs on metals and ongoing reimbursement pressure for healthcare customers could squeeze STERIS margins and slow big ticket equipment decisions, which would test that undervaluation story.
Find out about the key risks to this STERIS narrative.
Next Steps
Mixed messages around STERIS can be confusing, so it helps to examine the numbers yourself and decide whether the optimism holds up. To see what is driving that positive angle, review the 4 key rewards
Looking for more ideas beyond STERIS?
If STERIS has you thinking more broadly about portfolio upgrades, do not stop here. Fresh opportunities often show up where most investors are not looking yet.
- Target resilient value by scanning a concise shortlist of quality candidates through the 49 high quality undervalued stocks.
- Strengthen income potential by reviewing companies that feature robust payouts using the 6 dividend fortresses.
- Lower overall portfolio stress by focusing on companies that score well on stability through the 82 resilient stocks with low risk scores.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com